Petros Pharmaceuticals, Inc.
PTPI
$0.0919
-$0.0106-10.34%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.58M | 1.42M | 1.39M | -364.30K | 1.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.58M | 1.42M | 1.39M | -364.30K | 1.67M |
| Cost of Revenue | 287.00K | 329.10K | 331.80K | 158.10K | 408.50K |
| Gross Profit | 1.29M | 1.09M | 1.06M | -522.40K | 1.27M |
| SG&A Expenses | 2.30M | 2.29M | 2.71M | 2.88M | 2.00M |
| Depreciation & Amortization | 739.40K | 717.80K | 717.80K | 802.60K | 826.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.92M | 3.70M | 5.32M | 4.67M | 3.63M |
| Operating Income | -2.34M | -2.28M | -3.93M | -5.04M | -1.95M |
| Income Before Tax | -2.22M | -662.00K | -2.16M | 318.20K | -4.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.22M | -662.00K | -2.16M | 318.20K | -4.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.22M | -662.00K | -2.16M | 318.20K | -4.55M |
| EBIT | -2.34M | -2.28M | -3.93M | -5.04M | -1.95M |
| EBITDA | -1.60M | -1.56M | -3.21M | -4.24M | -1.12M |
| EPS Basic | -0.53 | -0.37 | -1.69 | -2.10 | -2.85 |
| Normalized Basic EPS | -0.14 | -0.06 | -0.28 | -0.71 | -1.34 |
| EPS Diluted | -0.53 | -0.37 | -1.69 | -2.10 | -2.85 |
| Normalized Diluted EPS | -0.14 | -0.06 | -0.28 | -0.71 | -1.34 |
| Average Basic Shares Outstanding | 9.83M | 7.39M | 4.76M | 2.38M | 2.12M |
| Average Diluted Shares Outstanding | 9.83M | 7.39M | 4.76M | 2.38M | 2.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
